Search results

74 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
UNC diabetes expert John Buse featured twice on WRAL
Buse led a global clinical trial on the new type-2 diabetes drug iDegLira, and he spoke to the local news station about the best ways to screen for the disease.
Located in News / 2016 / March
Diabetes drug lowers risk of cardiovascular complications, kidney disease
For the first time, a large clinical trial showed across-the-board cardiovascular benefit of a diabetes drug – liraglutide – a much-needed outcome for people with type 2 diabetes.
Located in News / 2016 / June
UNC clinical trials play crucial role in FDA approval for diabetes drug
Led by John Buse, MD, PhD, director of the UNC Diabetes Care Center, the clinical research of UNC doctors and the participation of thousands of patients culminates in a new, effective, and safe daily injectable drug to combat type-2 diabetes.
Located in News / 2016 / November
Diabetes researcher earns ADA grant to design nanoparticles to control blood sugar
The research by Zhen Gu, PhD, assistant professor in the UNC-NCSU joint department of biomedical engineering, aims to improve methods for delivering precise amounts of medications less frequently.
Located in News / 2015 / January
UNC diabetes researcher featured on WRAL
TV segment focused diabetes prevention and screening and featured John Buse, MD, PhD, chief, Division of Endocrinology, executive associate dean for clinical research.
Located in News / 2015 / March
Smart insulin patch could replace painful injections for diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
Located in News / 2015 / June
UNC researchers find two biomarkers linked to severe heart disease
The finding published in PLoS One suggests that elevated oxidized LDL cholesterol and fructosamine – a measure of glycated proteins in blood sugar – are signposts for the development of severe coronary disease, especially in females.
Located in News / 2015 / July
Diabetes drug metformin’s primary effect is in the gut, not the bloodstream
New study in Diabetes Care suggests new delayed-release metformin could help 40 percent of type 2 diabetes patients that currently can’t take metformin.
Located in News / 2015 / August
Biomedical engineer Zhen Gu, PhD, tabbed as top young innovator
The editors of the MIT Technology Review highlighted Gu’s work on a novel way to monitor and treat diabetes.
Located in News / 2015 / August
UNC’s Sue Kirkman, MD, co-authors first-ever ADA position paper on Type 1 diabetes
The newest American Diabetes Association treatment guidelines for the disease are in place at UNC Medical Center.
Located in News / 2014 / June